Evidence map›Paper›PMID 42453505›Full record

ArticleFrontiers in endocrinology2026

Clinicopathological features of breast cancer in Ukrainian women with BRCA1 c.181T>G (p.Cys61Gly) variant: a case series.

Nataliya Kitsera, Yaroslav Shparyk, Orest Tril, Ihor Protsko, Ivanna Duda, Olha Oleksyak, Andrii Hrynkiv, Irena Dovhanyk, Iryna Hrytsai, Iryna Tril and 8 more

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Nataliya KitseraLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Yaroslav ShparykLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Orest TrilLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Ihor ProtskoLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Ivanna DudaLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Olha OleksyakLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Andrii HrynkivLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Irena DovhanykLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Iryna HrytsaiLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Iryna TrilLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Halyna MakukhScientific and Medical Genetic Center "LeoGENE", Lviv, Ukraine.
Alina KruhlykovaMedical laboratory CSD, Kyiv, Ukraine.
Denys KozakovMedical laboratory CSD, Kyiv, Ukraine.
Sofiia LivshunMedical laboratory CSD, Kyiv, Ukraine.
Nazarii KobyliakMedical laboratory CSD, Kyiv, Ukraine.
Solomiia SobechkoScientific and Medical Genetic Center "LeoGENE", Lviv, Ukraine.
Myroslava OliyarnykLviv Oncologic Regional Treatment and Diagnostic Center, Lviv, Ukraine.
Oksana SulaievaMedical laboratory CSD, Kyiv, Ukraine.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Aim: This study aimed to characterize clinical presentation, tumor biology, and family history in Ukrainian women with BRCA1 c.181T>G variant. Materials and methods: We conducted a single-centre case series of women with primary breast cancer (BC) and/or ovarian cancer (OC) harbouring Results: Thirteen women aged 29-81 years (median 35 years) were included in this case series. Early-onset BC was recorded in 10 (76.9%) of patients diagnosed before 40 years. BC was the initial malignancy in 12 (92.3%) patients. OC occurred as a first tumor in 1 (7.7%) and as a subsequent cancer in 4 (30.8%) patients. Multiple malignancies were observed in 61.5% of patients, with intervals of 5-21 years between diagnoses. Family history revealed strong clustering of BC and OC across generations, often involving multiple affected relatives, consistent with hereditary breast and ovarian cancer syndrome phenotype. Among cases with known biomarker status (10/13), 2 were HER2-positive, 4 belonged to luminal-like type, and 4 cases represented triple negative BC. Most cases (10/13, 76.9%) were diagnosed at early tumor growth stage (pT1-2). However, more than half of primary tumors (8 of 13; 61.5%) had positive nodal status (pN1-2) reflecting invasive behaviour of cancer cells. Conclusions: This Ukrainian case series demonstrates that the

Indexed as

BRCA1 ProteinBreast NeoplasmsOvarian NeoplasmsAdultAgedAged, 80 and overBiomarkers, TumorFemaleGenetic Predisposition to DiseaseHumansMiddle AgedUkraineBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA1breast cancerc.181T>G variantfamily historygermline varianttumor biology

Identifiers

PMID42453505
PMCPMC13364604

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.